Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 4:35 p.m. ET in New York, New York.
紐約，2024年5月7日（GLOBE NEWSWIRE）——應用療法公司（納斯達克股票代碼：APLT）是一家處於臨床階段的生物製藥公司，該公司正在開發一系列針對未滿足高度未滿足醫療需求的分子靶標的新型候選藥物。該公司今天宣佈，它將在美國東部時間2024年5月14日星期二下午 4:35 在新州參加2024年加拿大皇家銀行資本市場全球醫療保健會議的爐邊談話紐約，紐約。
A live webcast for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at . A replay of the webcast will be archived on the Company's website for 90 days following the event.
該活動的網絡直播可在應用療法網站 “投資者關係” 部分下的 “活動” 頁面上觀看，網址爲。網絡直播的重播將在活動結束後的90天內在公司網站上存檔。
About Applied Therapeutics
關於應用療法
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Applied Therapeutics是一家處於臨床階段的生物製藥公司，正在開發一系列針對經過驗證的分子靶標的新型候選藥物，以應對大量未滿足的醫療需求。該公司的主要候選藥物govorestat是一種新型的中樞神經系統滲透劑Aldose還原酶抑制劑（ARI），用於治療中樞神經系統罕見的代謝性疾病，包括半乳糖血症、SORD缺乏症和 PMM2-CDG。該公司還在開發 AT-001，一種新型的強效急性呼吸道感染，用於治療糖尿病心肌病（dBCM），一種致命的心臟纖維化。臨床前產品線還包括 AT-003，這是一種用於治療糖尿病視網膜病變的急性呼吸道感染，旨在通過口服給藥時穿過眼背。
To learn more, please visit and follow the company on Twitter @Applied_Tx.
要了解更多信息，請在 Twitter 上訪問並關注該公司 @Applied_Tx。
Contacts
聯繫人
Investors:
Maeve Conneighton
(212) 600-1902
appliedtherapeutics@argotpartners.com
投資者：
Maeve Conneighton
(212) 600-1902
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
媒體：
media@appliedtherapeutics.com
譯文內容由第三人軟體翻譯。